Vascular Biogenics (NASDAQ:VBLT) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.06), MarketWatch Earnings reports. The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $2.30 million. Vascular Biogenics had a negative return on equity of 30.67% and a negative net margin of 2,724.02%.
NASDAQ:VBLT opened at $1.30 on Friday. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.01. The stock has a market cap of $43.42 million, a price-to-earnings ratio of -2.10 and a beta of -0.25. Vascular Biogenics has a 52 week low of $0.60 and a 52 week high of $3.10.
A number of equities analysts recently commented on the company. Zacks Investment Research raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Saturday, March 30th. Chardan Capital reaffirmed a “hold” rating and issued a $3.00 target price on shares of Vascular Biogenics in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Vascular Biogenics in a report on Thursday. Finally, ValuEngine cut Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st.
ILLEGAL ACTIVITY WARNING: “Vascular Biogenics (VBLT) Issues Quarterly Earnings Results” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://dakotafinancialnews.com/2019/05/17/vascular-biogenics-vblt-issues-quarterly-earnings-results.html.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Further Reading: How do analysts define an oversold condition?
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.